Identification | Back Directory | [Name]
Dolutegravir 2-Desfluoro Impurity | [CAS]
1863916-88-4 | [Synonyms]
4-Fluoro Dolutegravir Dolutegravir Impurity G Dolutegravir Impurity 47 Dolutegravir Impurity 50 Dolutegravir 2-Desfluoro Impurity (4R,12aS)-N-(4-fluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide 2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(4-fluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)- 2H-Pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide, N-[(4-fluorophenyl)methyl]-3,4,6,8,12,12a-hexahydro-7-hydroxy-4-methyl-6,8-dioxo-, (4R,12aS)-/Dolutegravir impurity Dolutegravir impurity 4/Defluoro Dolutegravir/(4R,12aS)-N-(4-Fluorobenzyl)-7-hydroxy-4-methyl-6,8-dioxo-3,4,6,8,12,12a-hexahydro-2H-pyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazine-9-carboxamide | [Molecular Formula]
C20H20FN3O5 | [MOL File]
1863916-88-4.mol | [Molecular Weight]
401.39 |
Hazard Information | Back Directory | [Uses]
Defluoro Dolutegravir is an impurity of Dolutegravir (D528800), a second generation HIV-1 integrase strand transfer inhibitor. Dolutegravir is currently in Phase III clinical trials for the treatment of HIV infection. Dolutegravir has been shown to potently inhibit HIV replication in cells such as peripheral blood mononuclear cells (PBMCs), MT-4 cells and CIP4 cells infected with a self-inactivating PHIV lentiviral vector. |
|
|